“Our partner, Labema Oy, is preparing for the first installation at a hospital who wants to understand how ASTar can improve their workflows and patient outcome,” said Thomas Fritz, CCO at Q-linea. “From an international perspective, the levels of antimicrobial resistance (AMR) are low in the Nordic countries. However, AMR is a global cross-border health threat, and rapid AST can have multiple positive impacts on patient outcomes.”

About ASTar Instrument and ASTar BC G- Kit
ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.